nach oben

Cancer Microenvironment

Erschienen in:

23.07.2018 | Original Article

Ascites IL-10 Promotes Ovarian Cancer Cell Migration

verfasst von: Denis Lane, Isabelle Matte, Perrine Garde-Granger, Paul Bessette, Alain Piché

Erschienen in: Cancer Microenvironment | Ausgabe 2-3/2018

Einloggen, um Zugang zu erhalten

Abstract

Ovarian cancer (OC) ascites is an inflammatory and immunosuppressive tumor environment characterized by the presence of various cytokines, chemokines and growth factors. The presence of high concentrations of these cytokines/chemokines in ascites is associated with a more aggressive tumor phenotype. IL-10 is an immunosuppressive cytokine for which high expression has been associated with poor prognosis in some cancers. However, its role on OC tumor cells has not been explored. Therefore, the aim of the current study was to elucidate the role of ascites IL-10 on the proliferation, migration and survival of OC cell lines. Here, we show that IL-10 levels are markedly increased in patients with advanced serous OC ascites relative to serous stage I/II ascites and peritoneal effusions from women with benign conditions. Ascites and IL-10 dose-dependently enhanced the proliferation and migration of OC cell lines CaOV3 and OVCAR3 but had no effect on cell survival. IL-10 levels in ascites positively correlated with the ability of ascites to promote cell migration but not proliferation. Depletion of IL-10 from ascites markedly inhibited ascites-induced OC cell migration but was not crucial for ascites-mediated cell proliferation. Taken together, our findings establish an important role for IL-10, as a component of ascites, in the migration of tumor cells.

Nur mit Berechtigung zugänglich

Bast RC, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415–428CrossRefPubMedPubMedCentral

Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC (2004) Focus on epithelial ovarian cancer. Cancer Cell 5:19–24CrossRefPubMed

Shen-Gunther J, Mannel RS (2002) Ascites as a predictor of ovarian malignancy. Gynecol Oncol 87:77–83CrossRefPubMed

Ayhan A, Gultekin M, Taskiran C, Dursun P, Firat P, Bozdag G, Celik NY, Yuce K (2007) Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer 17:68–75CrossRefPubMed

Ayantunde AA, Parsons SL (2007) Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 18:945–949CrossRefPubMed

Matte I, Lane D, Laplante C, Rancourt C, Piché A (2012) Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2:566–580PubMedCentralPubMed

Lane D, Matte I, Rancourt C, Piché A (2011) Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 11:210CrossRefPubMedPubMedCentral

Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M (2009) Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 29:2875–2884PubMed

Maccio A, Madeddu C (2012) Inflammation and ovarian cancer. Cytokine 58:133–147CrossRefPubMed

10.

Germano G, Allavena P, Mantovani A (2008) Cytokines as a key component of cancer-related inflammation. Cytokine 43:374–379CrossRefPubMed

11.

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867CrossRefPubMedPubMedCentral

12.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444CrossRefPubMed

13.

Lane D, Robert V, Grondin R, Rancourt C, Piché A (2007) Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt in human ovarian carcinoma cells. Int J Cancer 121:1227–1237CrossRefPubMed

14.

Lane D, Goncharenko-Khaider N, Rancourt C, Piché A (2010) Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 29:3519–3531CrossRefPubMed

15.

Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piché A (2012) Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer 11:84CrossRefPubMedPubMedCentral

16.

Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM (2007) Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9:820–829CrossRefPubMedPubMedCentral

17.

Matte I, Lane D, Laplante C, Garde-Granger P, Rancourt C, Piché A (2015) Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and –independent mechanisms. Int J Cancer 137:289–298CrossRefPubMed

18.

Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y (2015) The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 367:103–107CrossRefPubMed

19.

Jankovic D, Kugler DG, Sher A (2010) IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal Immunol 3:239–246CrossRefPubMedPubMedCentral

20.

Jankovic D, Kullberg MC, Feng CG, Goldszmid RS, Collazo CM, Wilson M, Wynn TA, Kamanaka M, Flavell RA, Sher A (2007) Conventional T-bet(+) Foxp3(−) Th1 cells are the major source of host protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 204:273–283CrossRefPubMedPubMedCentral

21.

Maynard CL, Weaver CT (2008) Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev 226:219–233CrossRefPubMedPubMedCentral

22.

Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15:61–76CrossRefPubMed

23.

Umetsu SE, Winandy S (2009) Ikaros is a regulator of Il10 expression in CD4+ T cells. J Immunol 183:5518–5525CrossRefPubMed

24.

Li C, Li H, Jiang K, Li J, Gai X (2014) TLR4 signaling pathway in mouse Lewis lung cancer cells promotes the expression of TGF-β1 and IL-10 and tumor cells migration. Biomed Mater Eng 24:869–875PubMed

25.

Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen M, Albino AP, Bander NH (1993) Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 55:96–101CrossRefPubMed

26.

Krüger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Hüls C, Blankenstein T, Diamantstein T (1994) Expression of interleukin 10 in human melanoma. Br J Cancer 70:1182–1185CrossRefPubMedPubMedCentral

27.

Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T, Gardeazabal J, Bilbao J, Canavate M, Galdeano AG, Izu R, Diaz-Ramon L, Raton JA, Diaz-Perez JL (2000) Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 83:847–852CrossRefPubMedPubMedCentral

28.

Chen Q, Daniel V, Maher DW, Hersey P (1994) Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 56:755–760CrossRefPubMed

29.

Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D (2001) Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Investig 19:239–247CrossRef

30.

Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383–1390PubMed

31.

Boulland ML, Meignin V, Leroy-Viard K, Copie-Bergman C, Brière J, Touitou R, Kanavaros P, Gaulard P (1998) Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. Am J Pathol 153:1229–1237CrossRefPubMedPubMedCentral

32.

Nowark M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, Tchorzewski H, Wilczynski J (2010) Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 31:375–383

33.

Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS, Martinez-Maza O (1992) Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 4:385–390CrossRefPubMed

34.

Mustea A, Konsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, Lichtenegger W, Sehouli J (2006) Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res 26:1715–1718PubMed

35.

Berger S, Siegert A, Denkert C, Kobel M, Hauptmann S (2001) Interleukin-10 in serous ovarian carcinoma cell lines. Cancer Immunol Immunother 50:328–333CrossRefPubMed

36.

Zhou J, Ye F, Chen H, Lv W, Gan N (2007) The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 35:290–300CrossRefPubMed

37.

Brencicova E, Jagger AL, Evans HG, Georgouli M, Laios AH, Montalto S, Mehra G, Spencer J, Ahmed AA, Raju-Kankipati S, Taams LS, Diebold SS (2017) Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on toll-like receptor-mediated dendritic cell activation in ovarian carcinoma. PLoS One 12:e0175712CrossRefPubMedPubMedCentral

38.

Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, Knutson KL (2017) IL10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res 77:6667–6678CrossRefPubMedPubMedCentral

39.

Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2:249–256CrossRefPubMed

40.

Lane D, Matte I, Laplante C, Garde-Granger P, Carignan A, Bessette P, Rancourt C, Piché A (2016) CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling. Mol Cancer 15:58CrossRefPubMedPubMedCentral

41.

Wu L, Deng Z, Peng Y, Han L, Liu J, Wang L, Li B, Zhao J, Jiao S, Wei H (2017) Ascites-derived IL-6 and IL-10 synergistically expand CD14⁺HLA-DR^−/low myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget 8:76843–76856PubMedCentralPubMed

42.

Kohno T, Mizukami H, Suzuki M, Saga Y, Takei Y, Shimpo M, Matsushita T, Okada T, Hanazono Y, Kume A, Sato I, Ozawa K (2003) Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 63:5091–5094PubMed

43.

Deying W, Feng G, Shumei L, Hui Z, Ming L, Hongqing W (2017) CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-met/PI3K/Akt and GRP78 signalling in ovarian cancer cells. Biosci Rep 37:BSR20160470CrossRefPubMedPubMedCentral

44.

Goldsmith ZG, Ha JH, Jayaraman M, Dhanasekaran DN (2011) Lysophosphatidic acid stimulates the proliferation of ovarian Cancer cells via the gep proto-oncogene Gα(12). Genes Cancer 2:563–575CrossRefPubMedPubMedCentral

45.

Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, Xu RC (2012) Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 59:228–236CrossRefPubMed

46.

Yousif NG (2014) Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway. Cell Biol Int 38:85–91CrossRefPubMed

47.

Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, Sun P, Huang S (2004) Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res 64:4209–4217CrossRefPubMed

48.

Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML, Wei LH (2011) IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 71:424–434CrossRefPubMed

49.

Furukama S, Soeda S, Kiko Y, Suzuki O, Hashimoto Y, Watanabe T, Nishiyama H, Tasaki K, Hojo H, Abe M, Fujimori K (2013) MCP-1 promotes invasion and adhesion of human ovarian cancer cells. Anticancer Res 33:4785–4790

50.

Sung WW, Wang YC, Lin PL, Cheng YW, Chen CY, Wu TC, Lee H (2013) IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Cancer Res 19:4092–4103

51.

Chen XD, Tang SX, Zhang JH, Zhang LT, Wang YW (2017) CIP2A, an oncoprotein, is associated with cell proliferation, invasion and migration in laryngeal carcinoma cells. Oncol Rep 38:1005–1012CrossRefPubMed

52.

Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J (2010) Biology of interleukin-10. Cytokine Growth Factor Rev 21:331–344CrossRefPubMed

53.

Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev 13:273–282CrossRef

54.

Rabinovich A, Medina L, Piura B, Huleihel M (2010) Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw 21:122–128PubMed

55.

Yao V, Platell C, Hall JC (2004) Peritoneal mesothelial cells produce inflammatory related cytokines. ANZ J Surg 74:997–1002CrossRefPubMed

56.

Alldredge J, Flies D, Higuchi T, Ma T, Adams SF (2014) Impaired interleukin-10 signaling and ovarian cancer growth in the peritoneal cavity. J Clin Oncol 32(15 suppl):e22094–e22094

Titel: Ascites IL-10 Promotes Ovarian Cancer Cell Migration
verfasst von: Denis Lane
Isabelle Matte
Perrine Garde-Granger
Paul Bessette
Alain Piché
Publikationsdatum: 23.07.2018
Verlag: Springer Netherlands
Erschienen in: Cancer Microenvironment / Ausgabe 2-3/2018
Print ISSN: 1875-2292
Elektronische ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-018-0215-3

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Ascites IL-10 Promotes Ovarian Cancer Cell Migration

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2018

Hypoxia Induces the Acquisition of Cancer Stem-like Phenotype Via Upregulation and Activation of Signal Transducer and Activator of Transcription-3 (STAT3) in MDA-MB-231, a Triple Negative Breast Cancer Cell Line

Skewed Signaling through the Receptor for Advanced Glycation End-Products Alters the Proinflammatory Profile of Tumor-Associated Macrophages

Tumor-Associated T-Lymphocytes and Macrophages are Decreased in Endometrioid Endometrial Carcinoma with MELF-Pattern Stromal Changes

Cerebrospinal Fluid Hyaluronan and Neurofibromatosis Type 2

T-Cell Clustering in Neoplastic Follicles of Follicular Lymphoma

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie